Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives

11/29/2021 | 07:56am EST

By Michael Dabaie

Krystal Biotech Inc. shares more than doubled in premarket trading after the company said a trial of Vyjuvek for dystrophic epidermolysis bullosa met its primary and secondary objectives.

Dystrophic EB is a rare and severe disease that affects the skin and mucosal tissues. The pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints, the company said.

Shares more than doubled, up 123% to $88.96 in premarket trading Monday.

Vyjuvek was well tolerated, with no drug-related serious adverse events or discontinuations, Krystal said.

The company said the biologics license application is on track to be submitted to U.S. Food and Drug Administration in the first half of 2022.

Krystal said it expects to submit a marketing authorization application in Europe shortly after the BLA.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

11-29-21 0756ET

All news about KRYSTAL BIOTECH, INC.
01/18KRYSTAL BIOTECH : Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand S..
PU
01/18KRYSTAL BIOTECH, INC. : Change in Directors or Principal Officers, Regulation FD Disclosur..
AQ
01/18BofA Securities Starts Krystal Biotech at Buy With $110 Price Target
MT
01/18Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand ..
AQ
01/18Krystal Biotech, Inc. Announces Management Changes
CI
2021INSIDER SELL : Krystal Biotech
MT
2021KRYSTAL BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements a..
AQ
2021Krystal Biotech Prices $200 Million Offering at $75/Share
MT
2021Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
AQ
2021Krystal Biotech Starts $200 Million Share Sale
MT
More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -63,7 M - -
Net cash 2021 358 M - -
P/E ratio 2021 -19,1x
Yield 2021 -
Capitalization 1 377 M 1 377 M -
EV / Sales 2021 -
EV / Sales 2022 3,13x
Nbr of Employees 75
Free-Float -
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | KRYS | US5011471027 | MarketScreener
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 55,29 $
Average target price 124,75 $
Spread / Average Target 126%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
George Chen Manager-Information Technology & CSV
Trevor Parry Senior Director-Scientific Affairs
Brittani Agostini Senior Manager-Clinical Operations
Stacie Oliver Clinical Affairs Scientist
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.-20.96%1 377
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624